Abstract 31P
Background
HRAS mutations have been found in 6% of HNSCCs. T cell exhaustion, defined as dysfunctional T cells stimulated by continuous antigen exposure. To guide immunotherapeutic approaches, we sought to assess the immune landscape of HRAS-mutant tumors by investigating the subpopulations of pre-exhausted and exhausted T cells.
Methods
We found 10 cases of HRAS mutant tumors and 39 cases of HRAS wild-type (WT) tumors. We sought to characterize exhausted CD8+ T cell subpopulations by measuring the expression of T-cell Factor-1 (TCF-1) and Programmed Cell Death-1 (PD-1) in the tumor's center (C) and periphery (P). Multiplex immunohistochemistry (IHC) was performed in FFPE tissue sections using three primary antibodies (PD1-CD8-TCF1/7), followed by analysis of a manually trained algorithm in Qupath software.
Results
HRAS mutant tumors present numerically higher numbers of total immune cells both in the C and the P than HRAS-WT tumors, that reached statistical significance only in the P (5123.17/mm2vs. 3527.93/mm2, p=0.002). In addition, the density of CD8+ T Cells was increased in both the C (694.10/mm2 vs. 356.02/mm2) and the P (851.10/mm2 vs. 333.30/mm2) in HRAS mutant tumors. Importantly, the percentage of pre-exhausted CD8 (+) T Cells was elevated in the P of HRAS mutant tumors (384.67/mm2vs. 51.18/mm2, p=0.040), indicating a possible association of response to ICB, since pre-exhausted T cells mediate the proliferative response to immunotherapy. On the contrary, exhausted T cells, defined as PD-1(+)TCF-1 (-) were more abundant in the C of HRAS mutant tumors compared to WT (13.77% vs. 2.67% of total CD8+ cells, p=0.022). Moreover, increased area occupied by CD11c+ dendritic cells and numbers of CD8+ T cells were found in regional lymph nodes from HRAS mutant patients (79.25% vs 38.80%, p=0.036 and 10160.43 vs 4438.28/mm2, p=0.036, respectively), consistent with data showing that maintenance of TCF1 by intratumoral T cells requires continuous migration from draining lymph nodes.
Conclusions
Pre-exhausted PD-1(+)TCF-1(+) T cells are significantly increased at the periphery of HRAS mutant tumors, suggesting a potential sensitivity of these tumors to ICB.
Legal entity responsible for the study
The authors.
Funding
Kura Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display
136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.
Presenter: G Lohith
Session: Poster Display